- The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's BCRX antiviral influenza therapy, Rapivab (peramivir injection), for approximately $7 million.
- The FDA approved Rapivab for acute uncomplicated influenza in patients six months and older who have been symptomatic for no more than two days.
- It is administered via an intravenous infusion for a minimum of 15 minutes at recommended doses of 600 mg/kg for adults and adolescents and 12 mg/kg for pediatric patients ages six months to 12 years.
- Also Read: FDA Lifts Clinical Hold On BioCryst's BCX9930 Program For Rare Blood Disorder.
- The Rapivab purchase by the HHS Administration will strengthen the nation's preparedness to respond to a potential pandemic influenza event.
- The order is the final of five purchase options from a $34.7 million contract the Centers for Disease Control and Prevention awarded in 2018 for procuring up to 50,000 doses of RAPIVAB over five years.
- With the fulfillment of this new order, BioCryst will have delivered all 50,000 doses to HHS under the contract.
- Price Action: BCRX shares are up 1.15% at $14.98 on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.